Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 7, 2013, Pages 947-951

  Muley, Thomas ^a,b   Dienemann, Hendrik ^a,b   Herth, Felix J F ^a,b   Thomas, Michael ^a,b   Meister, Michael ^a,b   Schneider, Joachim ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Member of the German Center for Lung Research   (Germany)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Asbestosis; Carcinoembryonic antigen; Lung cancer; Mesothelioma; Soluble mesothelin related proteins

Indexed keywords

ASBESTOS; CARCINOEMBRYONIC ANTIGEN; MESOTHELIN;

ADULT; AGED; ARTICLE; ASBESTOSIS; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 84880883059     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31828f696b     Document Type: Article

References (23)

1. Butz M. Beruflich verursachte Krebserkrankungen. Dokumentation des Berufskrankheiten-Geschehens in Deutschland. Deutsche gesetzliche Unfallversicherung, Sankt Augustin, Germany: 1-79, 2012.
2. Krismann M, Müller KM, Jaworska M, Johnen G. Pathological anatomy and molecular pathology. Lung Cancer 45S, S29-33: 2004.
3. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616.
4. Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;173:1155-1160.
5. Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008;85:265-72; discussion 272.
6. Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. J Thorac Oncol 2008;3:1317-1324.
7. Mezger J, Lamerz R, Permanetter W. Diagnostic significance of carcinoembryonic antigen in the differential diagnosis of malignant mesothelioma. J Thorac Cardiovasc Surg 1990;100:860-866.
8. Fuhrman C, Duche JC, Chouaid C, et al. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem 2000;33:405-410.
9. Schneider J. Tumor markers in detection of lung cancer. Adv Clin Chem 2006;42:1-41.
10. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (Eds). World Health Organization Classification of Tumours. Pathology and Genetics: Tumours of the lung, pleura, thymus and heart. WHO Press, Geneva, 2004. Pp. 1-344. Available at: http://www.iarc.fr/en/publications/pdfsonline/pat-gen/bb10/BB10. pdf. Accessed March 30, 2013.
11. Sobin LH, Gospodarowicz MK, Wittekind Ch (Eds). TNM Classification of Malignant Tumours, 7th Ed. Chicester, UK: John Wiley & Sons, 2009.
12. Parker JE: Radiological criteria: The use of chest imaging techniques in asbestos-related diseases. In Proceedings of an International Expert Meeting on Asbestos, Asbestosis and Cancer, People and Work, Finnish Institute of Occupational Health, Helsinki, Finland. Research Reports 1997; 14: 28-40.
13. Baur X, Clasen M, Fissler-Eckhoff A, Heger M, Hering KG, Hofmann- Preiss K, et al.: Diagnostics and expert opinion of Asbestos-induced occupational diseases. Interdisciplinary guideline of the German respiratory society and the German society of occupational and environmental medicine. Pneumologie 65: 159-188, 2011.
14. Hauser-Heidt G, Schneider J, Hackstein N, Litzelbauer D, Rau WS, Woitowitz HJ: Rundherdatelektasen als Pseudotumoren der Lunge: Eine neue MdE-relevante Folge arbeitsbedingter Asbestfaserstaub- Einwirkung. Zbl Arbeitsmed 2002; 52: 295-304.
15. International Labour Office (ILO). Guidelines for the Use of the ILO International Classification of Radiographs of Pneumoconiosis, Revised Edition 2000 (Occupational Safety and Health Series No 22). Geneva: International Labour Office, 2002.
16. Youden WJ. Index for rating diagnostic tests. Cancer 1950;3:32-35.
17. Blanquart C, Gueugnon F, Nguyen JM, et al. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. J Thorac Oncol 2012;7:883-889.
18. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data metaanalysis. J Clin Oncology 2012; 30: 1541-1549.
19. Van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. Lung Cancer 2008; 59: 350-354.
20. van der Bij S, Schaake E, Koffijberg H, Burgers JA, de Mol BA, Moons KG. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. Br J Cancer 2011;104:1325-1333.
21. Schneider J, Bitterlich N, Kotschy-Lang N, Raab W, Woitowitz HJ. A fuzzy-classifier using a marker panel for the detection of lung cancers in asbestosis patients. Anticancer Res 2007;27(4A):1869-1877.
22. Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 2011;6:1587-1593.
23. Ostroff RM, Mehan MR, Stewart A, et al. Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS ONE 2012; 7, 10: e46091.